摘要
The body of evidence investigating human epidermal growth factor receptor-2(HER2)directed therapy in patients with breast cancer(BC)has been growing within the last decade.Recently,the use of tyrosine kinase inhibitors(TKIs)has been of particular interest in the treatment of human malignancies.This literature commentary is intended to highlight the most recent findings associated with the widely-studied TKI agents and their clinical significance in improving the outcomes of HER2 positive BC.
基金
Supported by the Elsa U.Pardee Foundation Grant,No.671432(to Sahu RP)
NIH R21 Grant,No.ES033806(to Sahu RP).
